---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-003661"
form_type: "8-K"
ticker: "CRVS"
cik: "0001626971"
company_name: "Corvus Pharmaceuticals, Inc."
filed_at: "2025-06-04T23:59:59+00:00"
generated_at: "2026-05-19T23:57:23.483043+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Corvus soquelitinib Phase 1 atopic dermatitis data show statistically significant EASI improvement vs placebo

## Summary
- Soquelitinib met primary endpoint with statistically significant EASI improvement vs placebo at day 28 (p=0.036).
- Cohort 3 (200 mg BID) achieved 64.8% mean EASI reduction vs 34.4% for placebo.
- In cohort 3, 50% of evaluable patients (4/8) had a ≥4-point itch reduction (PP-NRS) at day 28.
- No safety signals; soquelitinib well tolerated with no DLTs and only one grade 1 AE (nausea).
- Extension cohort (200 mg BID, 8-week treatment) enrollment has been initiated.

## SEC filing metadata
- accession: 0001171843-25-003661
- form_type: 8-K
- ticker: CRVS
- cik: 0001626971
- company_name: Corvus Pharmaceuticals, Inc.
- filed_at: 2025-06-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1626971/000117184325003661/0001171843-25-003661-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1626971/000117184325003661/f8k_060425.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-003661
- JSON: https://secwatch.observer/filing/0001171843-25-003661.json
- Plain text: https://secwatch.observer/filing/0001171843-25-003661.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.